News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
ImmuPharma plc’s Cancer Drug Candidate IPP- 204106 Shows Complete Response to Tumours in Multiple Human Cancer Cell Lines
May 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, May 20, 2008-ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today pre-clinical data on its new cancer drug, IPP-204106.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
June 25, 2025
·
3 min read
·
Tristan Manalac
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
June 24, 2025
·
3 min read
·
Tristan Manalac
Artificial intelligence
In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker
June 24, 2025
·
2 min read
·
Tristan Manalac
